A research group led by Catherine Smith from St John’s Institute of Dermatology described humoral and cellular immunity.
It is not fully understood the impact that COVID-19 has on psoriasis patients.
IPC is pleased to welcome Arcutis Biotherapeutics, Inc. as a 2022 Bronze Level Corporate Member.
Meet the three new key opinion leaders who have been elected to join our board.
IPC’s newly appointed appointed officers take their roles beginning January 1, 2022.
The European Academy of Dermatology and Venerelogy 30th Annual Congress (EADV) was packed with science and clinical practice updates. You can download the full report or read a brief look at some of the highlights.
The ESDR congress included many noteworthy psoriasis presentations from both IPC councilors and experts from around the world. You can download the full report or read a brief look at some of the highlights.
Biologics and biosimilars have created many new options in psoriasis treatment for patients worldwide, but patients worldwide face barriers to acquiring them. This has led IPC Councilor Dr. Matias Maskin to reconsider what success means for psoriasis patients.
The safety of treatment for immune-mediated diseases like psoriasis during the COVID-19 pandemic is a matter of concern. In an Israeli population-based nested case-control study using the Clalit Health Services database, 3,151 patients with psoriasis that tested positive for SARS-CoV-2 infection were identified.
In the April 2021 issue of the Lancet, four of our esteemed colleagues in the IPC published an updated and comprehensive review of the current pieces of knowledge on psoriasis. It is a very well-written review covering all aspects of psoriasis
Because of the growing body of evidence indicating sex differences in the clinical outcomes of coronavirus disease 2019 (COVID-19) infection, the IMPACT Research Team from Yale University investigated sex differences in viral loads, SARS-CoV-2-specific antibody titers, plasma cytokines, as well as blood cell phenotyping in COVID-19 patients.
Satveer Mahil joins the group of respected IPC psoriasis experts who are working to advance knowledge and enhance the care of psoriasis patients.
